Metagenomi science chief departs, just a few months after IPO

When As­traZeneca R&D ex­ec­u­tive Mene Pan­ga­los joined the com­pa­ny in 2010, the UK drug gi­ant was fac­ing ex­is­ten­tial threats: shrink­ing sales, a meek pipeline and

Bris­tol My­ers Squibb is tak­ing its clin­i­cal tri­als to where di­verse pop­u­la­tions of peo­ple live and work to help boost di­ver­si­ty in its stud­ies. Its

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it